LinKinVax Just Completed a New Round of Financing, Initiated in 2022, for a Total of €7,3 M streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
LinKinVax Just Completed a New Round of Financing, Initiated in 2022, for a Total of €7,3 M finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
TO ACCELERATE THE DEVELOPMENT OF ITS INNOVATIVE VACCINE PLATFORM LinKinVax, a clinical-stage biotechnology companyis announcing completion of a €4.350 million seed capital funding round. It was led
Share this article
-
Pre-clinical in vitro research from the Mondor Institute of Biomedical Research (INSERM U955) has shown evidence for the effectiveness of alisporivir against the replication of
SARS-COV-2 (COVID-19)
-
A randomized, investigator-initiated, phase II study, conducted by the AP-HP (Greater Paris University Hospitals), has been launched to assess the efficacy and safety of the compound in 90 hospitalized COVID-19 patients from multiple centers in France
-
Debiopharm has opted to forgo any financial benefit from treatment and pledges to donate all proceeds to a non-profit foundation dedicated to infectious disease research
LAUSANNE, Switzerland, Jan. 18, 2021 /PRNewswire/
Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company,